Compare Novo Nordisk A/S (NVO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Redwire Corporation — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while Redwire Corporation trades at $13.62 (market cap $3.38B). The key difference: Novo Nordisk A/S is far larger — about 61.5× Redwire Corporation's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| NVO | RDW | |
|---|---|---|
Market Cap | $207.85B | $3.38B |
Sector | Health | Technology |
52-Week High | $63.98 | $25.90 |
52-Week Low | $35.29 | $5.06 |
Enterprise Value | $222.55B | $2.91B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Redwire (RDW) trades at $13.57, up 3.43% with strong technical momentum as the stock approaches its consensus price target of $17.50. The company reported record Q2 2026 revenue of $117.1 million and a $542.1 million backlog, though it continues to post significant net losses with a -57.26% margin. Analyst sentiment remains overwhelmingly positive with 80% buy ratings, while technical indicators show bullish moving averages but overbought RSI conditions.
Redwire presents a growth story fueled by defense contracts and space technology, but faces substantial execution risk given persistent losses and negative cash flow from operations. The stock's upside depends on successful margin improvement and backlog conversion, while downside risk remains from dilution and delayed profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
